Arcus Biosciences, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a quarter-only filing. Arcus is a clinical-stage biopharmaceutical company with no products approved for sale and no product-sale revenue.
Business context
The company is developing immuno-oncology and related therapies. Its anti-TIGIT antibody domvanalimab was being evaluated in four Phase 3 trials; the broader clinical portfolio included 13 studies. Gilead is a major partner, with licenses or options covering several programs. Arcus and Gilead generally share development costs for opted-in programs, and Arcus retains a U.S. co-promotion option under specified terms.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $112 million | $383 million |
| Research and development expense, net of recoveries | $288 million | $257 million |
| General and administrative expense | $104 million | $72 million |
| Operating income (loss) | $(280) million | $54 million |
| Net income (loss) | $(267) million | $53 million |
| Operating cash flow | $438 million provided | $256 million used |
- Revenue came from collaboration, licensing and development arrangements, not product sales. Gilead accounted for 96% of 2022 revenue.
- Cash, cash equivalents and marketable securities totaled $1.138 billion at year-end, versus $681 million a year earlier. Management estimated funds would support planned operations into 2026; this depends on assumptions that could change.
- Current assets were $1.067 billion and current liabilities $193 million. Deferred revenue totaled $452 million, principally related to Gilead collaboration obligations.
- The filing does not report conventional borrowings in the presented balance sheet. It reports a $17 million liability for sale of future royalties to BVF. Undiscounted operating lease commitments totaled $159 million through 2031.
- No product-sales margin is available. The company remains loss-making and expects substantial development spending.
Material changes and unusual items
- Revenue fell 71% year over year, primarily because 2021 included substantial revenue recognized when Gilead exercised program options. In 2022, Arcus recognized $107 million under the Gilead agreement.
- R&D expense rose 12%, despite higher partner cost reimbursements: gross collaboration reimbursements were $161 million in 2022 versus $25 million in 2021. Higher clinical, manufacturing and personnel costs drove the increase.
- Gilead’s $725 million option payment, received in January 2022 following 2021 option exercises, contributed to the year’s positive operating cash flow and higher year-end investments. The cash-flow result should not be treated as recurring operating generation.
- 2022 included $4 million of cumulative catch-up collaboration revenue due to updated estimates of future effort and clinical-trial assumptions. Management said a hypothetical 10% change in estimated total effort could change current-year related revenue by as much as $7 million.
- Accumulated deficit was $542 million at year-end. The company reported an unqualified financial-statement audit opinion and effective internal control over financial reporting.
Outlook, commentary and risks
- Management expects R&D spending to rise as late-stage trials expand, new programs advance, and manufacturing and development capabilities grow. The filing gives no earnings or revenue guidance.
- For 2023, Arcus expected PFS and overall-survival data from the randomized portion of the ARC-8 pancreatic cancer study. It also expected to advance its first inflammation-targeted small molecule into preclinical development.
- In December 2022, interim ARC-7 results showed median PFS of 12.0 months for the domvanalimab/zimberelimab doublet and 10.9 months for the triplet, versus 5.4 months for zimberelimab alone. Confirmed response rates were 41%, 40% and 27%, respectively. These are interim clinical results; follow-up and outcome data remain important.
- Key risks include clinical-trial failure or delay, competition and patient enrollment, reliance on Gilead and other partners, and dependence on third-party manufacturers. Arcus cited single-source supply for investigational products and an exclusive WuXi Biologics manufacturing relationship for zimberelimab.
- Additional risks include uncertainty of regulatory approval and commercialization, reimbursement and pricing pressure, intellectual-property disputes, supply-chain disruption, and cybersecurity threats. The company disclosed detected system intrusions and a successful social-engineering attack, while stating its investigations found no material operational impact or information compromise.
- Arcus reported no material legal proceedings. It had no cash-dividend history and did not anticipate dividends in the foreseeable future.
Important facts for investors to verify
- Whether domvanalimab’s Phase 3 trials produce durable, statistically persuasive results and how interim ARC-7 findings mature.
- The timing and results of ARC-8 data and other stated clinical milestones.
- Cash burn and runway as trial activity expands, including whether the “into 2026” estimate remains supportable.
- Future Gilead and Taiho payments, cost-sharing terms, program options and the degree of revenue concentration in collaboration partners.
- Manufacturing resilience, especially single-source supply and WuXi-related operational or geopolitical exposure.